OS Therapies Inc

OSTX chart

OS Therapies Inc news

• A 9.95% ownership cap limits an OS Therapies (OSTX) holder’s preferred-stock conversion and warrant exercise.

  Stock Titan · Nov 10, 1:53 PM EST

• Roth MKM Maintains OS Therapies(OSTX.US) With Buy Rating, Maintains Target Price $7

  Moomoo · Nov 10, 12:58 PM EST

• OS Therapies Initiates U.K. MHRA Conditional Marketing...

  Quantisnow · Nov 10, 8:21 AM EST

• OS Therapies Initiates U.K. MHRA Conditional Marketing Authorisation Application for Herlystic (OST-HER2) in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma

  Yahoo Finance · Nov 10, 8:15 AM EST

• OS Therapies (OSTX) Starts UK Application for Herlystic

  TradingView · Nov 10, 8:15 AM EST

• OS Therapies rises 2.03% in Friday's session

  Global Banking & Finance Review · Nov 6, 3:00 AM EST

• OS Therapies Completes Requalification of Phase 2b Herlystic (OST-HER2) Drug Substance for Confirmatory Phase 3 Trial

  Yahoo Finance · Nov 5, 8:00 AM EST

• OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million

  Yahoo Finance · Oct 19, 8:30 AM EDT

• Rubenstein Public Relations Named Agency of Record for OS Therapies

  Yahoo Finance · Oct 8, 9:22 AM EDT

• OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma

  Yahoo Finance · Oct 7, 8:30 AM EDT

• OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial

  Yahoo Finance · Oct 6, 8:30 AM EDT

• OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer

  Yahoo Finance · Oct 1, 8:30 AM EDT

OS Therapies Inc key financials

Calendar-year figures as reported to the SEC in XBRL filings.

Recent SEC filings

• 8-KCURRENT REPORT2026-10-19
• 8-KCURRENT REPORT2026-10-05
• 8-KCURRENT REPORT2026-09-10
• 8-KCURRENT REPORT2026-09-09
• 8-KCURRENT REPORT2026-08-21
• 10-QQUARTERLY REPORT2026-08-14
• 8-KCURRENT REPORT2026-08-12
• 8-KCURRENT REPORT2026-08-06
• 8-KCURRENT REPORT2026-07-29
• DEF 14APROXY STATEMENT2026-07-24
• 8-K/AAMENDMENT NO. 1 TO FORM 8-K2026-07-07
• 8-KCURRENT REPORT2026-07-02

About OS Therapies Inc

Ticker

OSTX (NYSE)

Industry

Pharmaceutical Preparations

Headquarters

Rockville, MD

Incorporated in

DE

Fiscal year end

December 31

SEC CIK

1795091

Frequently asked questions